



EUROPEAN ASSOCIATION OF  
PHARMA BIOTECHNOLOGY



## Newsletter July 2010

Dear EAPB members and EAPB friends,

In the July edition of EAPB's newsletter you read about the upcoming events we organize or co-organize – especially we want to draw your attention to EAPB's special interest groups in October. We invite all our members to the members' assembly on October 4, 2010 and inform about some personalities.

I hope you enjoy reading the summer edition of EAPB's newsletter, because it provides additional information which is not available on other occasions or platforms.

I'm open to getting your feedback, comments, opinion – and contribution to the next EAPB newsletter which is planned for October 2010.

Yours sincerely,

[Marion Kronabel](#)

Managing Director EAPB

### Content of this issue

- ▶ [Special Interest Group "Regenerative Medicine"](#)
- ▶ [Special Interest Group "Regulatory Aspects for Biopharmaceuticals"](#)
- ▶ [Events, workshops, conferences with EAPB as partner](#)
- ▶ [EAPB's General Meeting](#)
- ▶ [Collaboration with European Biotechnology Network](#)
- ▶ [Personalities](#)

### Special Interest Group "Regenerative Medicine"

In combination with the biotech trade fair **Biotechnica** the European Association of Pharma Biotechnology – EAPB - holds its next workshop of regenerative medicine on **October 4, 2010**

Advanced Therapy Medicinal Products (ATMPs) are tightly regulated by the European Medicines Agency (EMA) with the intention to ensure the safety, efficacy as well as the good quality of the products. A well defined risk evaluation in order to cover the whole development process and not only quality or safety risks should be set-up. For example, tumorigenicity, genome stability, biodistribution are now among the top issues during non-clinical and clinical

development and need to be addressed for stem cell-based products early. A key point is hereby an efficient communication with the regulators as early as possible to avoid detours or even worst failures. So the scientific advice became a very powerful tool to find the right way through the jungle of guidelines, reflection papers, regulations and the expectation of the regulators.

The aim of this workshop is to bring together experts on regulation and developers from academia and industry in order to share experiences and handy tips for the process of scientific advice by regulatory agencies and for the development of cell-based products in Europe.

Presentations will be about the significance of scientific advice for small enterprises and the dos and don'ts during the process of scientific advice as well as quality standards of stem cell based therapies.

[Preliminary program](#)

[Registration for SIG on October 4, 2010](#)

[Registration to become a SIG member in the future](#)

Location: Biotechnica, Conference Centre Hannover Messe

Time: October 4, 2010, 1:30 – 5:30 pm

Registration fee:

150,- € for non-members

50,- € for existing members of SIG "Regenerative Medicine"

[>> back](#)

---

## **Special Interest Group "Regulatory Aspects for Biopharmaceuticals"**

**In combination with the biotech trade fair Biotechnica the European Association of Pharma Biotechnology – EAPB - holds its next workshop of regulatory aspects on October 4, 2010**

In contrast to many other sciences, the biopharmaceutical sciences are heavily impacted by national and international regulations so that developers and manufacturers of biopharmaceutical drug substances and drug products need profound knowledge of the current drug regulations in the field as well as of current regulatory opinions. On the other hand, drug regulations must consider what is scientifically feasible and sensible. This balance is achieved the best by frequent exchanges between industry, academia and regulatory bodies.

The SIG Regulatory Aspects for Biopharmaceuticals wants to give this exchange room and targets at taking up current hot topics in presentations and discussion forums.

The aim of this workshop is to bring together experts on regulation and experts from academia and industry in order to share experiences and discuss different opinions on two selected current hot topics: "Quality by Design" and "Subvisible Particles".

[Preliminary program](#)

[Registration for SIG on October 4, 2010](#)

[Registration to become a SIG member in the future](#)

Location: Biotechnica, Conference Centre Hannover Messe

Time: October 4, 2010, 1:30 – 5:30 pm

Registration fee:

150,- € for non-members

50,- € for existing members of SIG "Regulatory Aspects for Biopharmaceuticals"

[>> back](#)

---

**Events, workshops, conferences with EAPB as partner**

For remaining 2010 we select some events and want to draw your attention to them.

### Biospine 3

Amsterdam, September 1 - 4, 2010

### BIOSPINE 3

3rd International Congress Biotechnologies for Spinal Surgery

Amsterdam, The Netherlands

September 1st-4th, 2010

The topic Biotechnologies in Spinal Surgery has created a great interest during the last years. The symposium will address cellular therapies, application for growth factors, regeneration and degeneration of intervertebral disc, which have already been topics of previous conferences. Another target of the meeting is to offer insight into the fields of embryonic, pluripotent and adult stem cells, skeletal application of polymeres, spinal cord repair and cellular repair strategies. Further advances in nanoparticles for visualisation, smart scaffolds and the opportunities for conservative therapies are critically important to the debate.

### 14th International Biotechnology Symposium

Rimini, September 14 - 18, 2010



The overall aim of 14th IBS is to explore the advances, frontiers and applications of biotechnology for a healthier and more sustainable future and a knowledge-based bio-economy all over the world, and to strengthen relations between industry, research laboratories, government agencies, the private sector and universities on such strategic issues for human sustainability.

### Pharmaceutical Sciences World Conference PSWC 2010

New Orleans, November 14 - 18, 2010



In 2010 FIP (International Pharmaceutical Federation) and AAPS (American Association of Pharmaceutical Scientists) have agreed to hold the Pharmaceutical Sciences World Congress - PSWC - and the AAPS Annual Meeting together in New Orleans, Louisiana, USA from 14 - 18 November.

The objective of this joint meeting is for the education and benefit of the members of each organization and the constituencies that they represent. The programming, exposition, and other events will provide maximum educational opportunities.

### Bio-Europe 2010

Munich, November 15 - 17, 2010



The 16th annual BIO-Europe event is the largest biotechnology partnering conference held in Europe. Over 2,500 global decision makers from biotechnology, pharma and finance annually attend BIO-Europe to identify new business opportunities and develop strategic relationships. BIO-Europe features the industry's most advanced web-based partnering system, partneringONE, enabling delegates from all parts of the biotechnology value chain to quickly identify engage and enter into strategic relationships that drive their business successfully forward.

Detailed information about all mentioned symposia and conferences you find on the [EAPB website](#)

[>> back](#)

---

**EAPB's General Meeting**

**Save the date: October 4, 2010**

The next EAPB's members' assembly will be held in Hannover Convention Center, Room 17, during Biotechnica on October 4, 2010, 5.30 pm. The President of EAPB will send personal invitations with final agenda at beginning of August.

Topics are

- reporting about activities since last assembly by the executive committee and planning the upcoming activities / enhancement of service offers of the association
- approving the actions of the executive committee
- election of executive committee and appointing an independent auditor
- miscellaneous

[>> back](#)

---

## **Collaboration with European Biotechnology Network**

Additional to the existing collaborations with European international organisations EAPB has started a partnership with the [European Biotechnology Network](#) as both associations target to facilitate cooperation between professionals in biotechnology and life sciences in Europe. Being partner of the Network means as well that EAPB can now provide a members' journal, a free subscription to "[European Biotechnology News](#)", which normally costs 100,- € annually. Additionally EAPB members gain a further publishing platform now. So please send your exciting news to [managing.director](#), not only for our newsletter or website but as well for European Biotechnology News.

From some EAPB members we only have the currently valid email addresses. Therefore to make sure that you get the journal please send your postal address coordinates (preferably in outlook vcard format) to [managing.director](#) .

[>> back](#)

---

## **Personalities**

Three of our board members have recently started new professional activities. As we are a network, it might be useful for you to know about these updated responsibilities.

### **Henrik L. Luessen**

InSCREENEx GmbH in Braunschweig, Germany, appoints Dr. Henrik L. Luessen as Chief Business Officer, being responsible for business and strategic development with focus on the company's innovative "SCREENflex" and "CI-SCREEN" product solutions which enable improved biologically relevant tests in vitro at all stages of the drug development process. [Read more...](#)

### **Jan van de Winkel**

Genmab A/S in Copenhagen, Denmark, announces a change in management: Prof. Dr. Jan G. J. van de Winkel is appointed new CEO, following Lisa N. Drakeman, who retires. Jan van de Winkel has over 20 years experience in the therapeutic antibody field and has served as Scientific Director and Vice President of Medarex Europe prior to co-founding Genmab. [Read more...](#)

### **Wieland Wolf**

ProBioGen AG in Berlin, Germany, appoints Dr. Wieland Wolf as new CEO. Minapharm Pharmaceuticals,

Cairo, acquired 95% of share capital of ProBioGen, an internationally renowned cell line development and contract manufacturing specialist. The complimentary expertise of the two companies enables the continued development of proprietary technologies for biopharmaceutical products. [Read more...](#)

[>> back](#)

---

Please unsubscribe - [here](#)

Please [send EAPB newsletter](#) as well to the following email address

Please update my [postal address](#)

---



---

The **European Association of Pharma Biotechnology (EAPB)** is the representative of pharmaceutical biotechnology in Europe and dedicated to the advancement of biotechnology in pharmaceutical sciences, specifically as applied to medicinal drugs, industrial materials, processes, products and their associated issues.

As a non-profit organization **EAPB** provides a central network linking academia, industry and regulatory bodies. Accordingly its members are professionals from biotechnology and pharmaceutical companies, governmental authorities, academia and scientific organizations.

Events organized by **EAPB** promote collaborations between science and industry in the sector of pharmaceutical biotechnology. Specifically the technology transfer focused Science to Market Conferences intent to enhance the economical output of scientific research and direct them into marketable technologies and biopharmaceutical products.

**Editorial responsibility**

**EAPB** assumes responsibility for content according to German media law. If you have any queries regarding the association or require any further information, do not hesitate to contact us.

**European Association Pharma Biotechnology**

[Dr. Marion Kronabel](#), Managing Director